Aurx.Pk
AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Business. AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.
AURX.PK exhibits a negative equity position of -$956,560, indicating a significant financial challenge, and a debt-to-equity ratio of -0.52, which suggests the company is leveraging debt to fund operations. The liquidity position is moderate, with a current ratio of 1.06, implying the company has just enough current assets to cover its current liabilities. The operating cash flow is negative at -$864,970, and the free cash flow is -$2,701,520, indicating the company is not generating sufficient cash from operations to sustain or grow its business.
Profitability metrics show a return on equity of 2.63, which is positive but modest, and a return on assets of -1.36, indicating that the company is not effectively utilizing its assets to generate profit. The gross profit of $2,217,960 is offset by a net loss of -$2,512,220, highlighting the company's struggle to convert gross profit into net income.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases its exposure to market-specific risks. The capital expenditure of -$274,760 suggests the company is not investing in long-term growth, which could limit its future capacity to expand or innovate.
Looking ahead, the company is expected to maintain a negative operating income, with no significant improvement in the near term. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag.
Recent investor relations data show a mean price target of $3.00, with a median and high price target also at $3.00, and a mean recommendation of 2.00, indicating a cautious outlook from analysts. No strong buy recommendations were issued, with only one buy recommendation and no holds, suggesting limited confidence in the stock's near-term performance.
- AURX.PK is operating with a negative equity position and a negative net cash position, indicating significant financial distress.
- The company's liquidity is moderate, with a current ratio of 1.06, but its operating and free cash flows are negative, signaling poor cash generation.
- The return on equity is positive but low, while the return on assets is negative, indicating inefficient asset utilization.
- The company is not investing in capital expenditures, which could hinder future growth and innovation.
- Analysts have a cautious outlook, with a mean price target of $3.00 and no strong buy recommendations.
- The company's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,03 |
| Revenue | —no estimate | —no estimate | 5,4M USD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- AURX.PK Market data — financials · 2026-05-27
- Nuo Therapeutics Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Net income (YoY) (2025-12-31 vs 2024-12-31): -8.1%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 261.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 55.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -286.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 61.2%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 93.5%Derived (calculated)
- Return on assets (FY 2025-12-31): -136.1%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 77.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): -2.93xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -2.4%Derived (calculated)
- Return on equity (FY 2025-12-31): 262.6%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 108.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.06xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 314.7%Derived (calculated)
- Cash & equivalents (annual): USD 548.95KSEC XBRL filing
- Shareholders' equity (annual): USD -956.56KSEC XBRL filing
- Operating income (annual): USD -2.52MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating cash flow (annual): USD -864.97KSEC XBRL filing
- Gross profit (annual): USD 2.22MSEC XBRL filing
- Total assets (annual): USD 1.85MSEC XBRL filing
- Cost of revenue (annual): USD 1.1MSEC XBRL filing
- Net income (annual): USD -2.51MSEC XBRL filing